- Home
- ALVO vs AKRO Comparison
ALVO vs AKRO Comparison
Compare ALVO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- AKRO
- Stock Information
- Founded
- ALVO 2013
- AKRO 2017
- Country
- ALVO Luxembourg
- AKRO United States
- Employees
- ALVO N/A
- AKRO N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- AKRO Health Care
- Exchange
- ALVO Nasdaq
- AKRO Nasdaq
- Market Cap
- ALVO 2.5B
- AKRO 2.8B
- IPO Year
- ALVO N/A
- AKRO 2019
- Fundamental
- Price
- ALVO $9.38
- AKRO $42.39
- Analyst Decision
- ALVO Buy
- AKRO Strong Buy
- Analyst Count
- ALVO 1
- AKRO 9
- Target Price
- ALVO $18.00
- AKRO $76.29
- AVG Volume (30 Days)
- ALVO 140.4K
- AKRO 1.1M
- Earning Date
- ALVO 05-07-2025
- AKRO 05-16-2025
- Dividend Yield
- ALVO N/A
- AKRO N/A
- EPS Growth
- ALVO N/A
- AKRO N/A
- EPS
- ALVO 0.34
- AKRO N/A
- Revenue
- ALVO $587,890,000.00
- AKRO N/A
- Revenue This Year
- ALVO $33.92
- AKRO N/A
- Revenue Next Year
- ALVO $45.74
- AKRO N/A
- P/E Ratio
- ALVO $27.67
- AKRO N/A
- Revenue Growth
- ALVO 413.92
- AKRO N/A
- 52 Week Low
- ALVO $7.35
- AKRO $17.86
- 52 Week High
- ALVO $14.65
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ALVO 58.67
- AKRO 52.42
- Support Level
- ALVO $7.90
- AKRO $41.60
- Resistance Level
- ALVO $8.50
- AKRO $46.47
- Average True Range (ATR)
- ALVO 0.39
- AKRO 2.05
- MACD
- ALVO 0.18
- AKRO 0.37
- Stochastic Oscillator
- ALVO 67.72
- AKRO 55.60
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.